| scholarly article | Q13442814 |
| P50 | author | Kanwal Rehman | Q55240521 |
| Shuqing Chen | Q42968776 | ||
| Muhammad Sajid Hamid Akash | Q49332193 | ||
| P2093 | author name string | Shuqing Chen | |
| Muhammad Sajid Hamid Akash | |||
| P2860 | cites work | The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan | Q24673691 |
| Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria | Q24799750 | ||
| In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii | Q24804214 | ||
| Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 | Q28179431 | ||
| Interleukin-1-receptor antagonist in type 2 diabetes mellitus | Q29619001 | ||
| Protein instability in poly(lactic-co-glycolic acid) microparticles. | Q30327666 | ||
| Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris | Q33281513 | ||
| Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist | Q33287308 | ||
| Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | Q33326938 | ||
| Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat | Q33501717 | ||
| Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine | Q33756245 | ||
| Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys | Q34155234 | ||
| Block copolymer micelles for drug delivery: design, characterization and biological significance | Q34184381 | ||
| Pegylation: a novel process for modifying pharmacokinetics | Q34340198 | ||
| Interleukin-1 receptor antagonist as therapy for inflammatory disorders | Q34452084 | ||
| Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2 | Q34480036 | ||
| Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery | Q34542874 | ||
| A thermally responsive biopolymer for intra-articular drug delivery | Q34564365 | ||
| Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats | Q34586474 | ||
| Pharmaceutical strategies utilizing recombinant human serum albumin | Q34690229 | ||
| Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic | Q34707694 | ||
| Pegylation: engineering improved pharmaceuticals for enhanced therapy | Q34782103 | ||
| Effect of pegylation on pharmaceuticals | Q35075776 | ||
| Synthesis and structural characterization of poly(LGGVG), an elastin-like polypeptide. | Q53916382 | ||
| [Inhomogeneous expression of fusion protein HSA/IL1ra in Pichia pastoris]. | Q54423813 | ||
| Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice | Q68177118 | ||
| Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists | Q70466614 | ||
| Effect of surfactants on the physical stability of recombinant human growth hormone | Q71750056 | ||
| Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria | Q73035266 | ||
| Purification of recombinant proteins by fusion with thermally-responsive polypeptides | Q73143445 | ||
| Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel | Q73691324 | ||
| Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients | Q73720159 | ||
| De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: a novel concept and capability | Q73788042 | ||
| Preparation and evaluation of poly(L-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing | Q74320026 | ||
| In situ delivery of passive immunity by lactobacilli producing single-chain antibodies | Q74381949 | ||
| Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats | Q77941051 | ||
| Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin | Q78532081 | ||
| Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization | Q79507549 | ||
| Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin | Q79905970 | ||
| Aggregation-resistant domain antibodies selected on phage by heat denaturation | Q80427731 | ||
| AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure | Q81117258 | ||
| High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation | Q81367570 | ||
| Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris | Q81461019 | ||
| Statistical optimization of insulin-loaded Pluronic F-127 gels for buccal delivery of basal insulin | Q83150156 | ||
| [Purification of fusion protein HSA/IL1ra and its bioactivity] | Q84019102 | ||
| Direct deposited porous scaffolds of calcium phosphate cement with alginate for drug delivery and bone tissue engineering | Q84026641 | ||
| Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials | Q84830552 | ||
| Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein | Q35369090 | ||
| Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. | Q35474257 | ||
| Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C | Q35551591 | ||
| Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres | Q35694277 | ||
| The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). | Q35743530 | ||
| Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology | Q35813745 | ||
| Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli | Q35896400 | ||
| Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins | Q36162174 | ||
| Interleukin-1 and neuronal injury | Q36202191 | ||
| The role of inflammation in CNS injury and disease | Q36364424 | ||
| Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis | Q36496490 | ||
| Polymer conjugates as anticancer nanomedicines | Q36561667 | ||
| Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease | Q36741828 | ||
| Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling | Q36842606 | ||
| The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders | Q36859216 | ||
| Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention | Q36919403 | ||
| Interleukin-1 and inflammatory neurodegeneration | Q36979642 | ||
| Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. | Q37027164 | ||
| Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives | Q37033403 | ||
| How to achieve sustained and complete protein release from PLGA-based microparticles? | Q37046238 | ||
| Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. | Q37096677 | ||
| Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles | Q37201079 | ||
| Systemic infection, inflammation and acute ischemic stroke. | Q37267721 | ||
| IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat | Q37310711 | ||
| Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. | Q37319117 | ||
| The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia | Q37325272 | ||
| Peptide-based Biopolymers in Biomedicine and Biotechnology | Q37362252 | ||
| ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy | Q37666971 | ||
| Delivery of therapeutic proteins | Q37668486 | ||
| Drug delivery to solid tumors by elastin-like polypeptides | Q37764989 | ||
| Strategies for extended serum half-life of protein therapeutics | Q37921435 | ||
| Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus | Q37978230 | ||
| Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. | Q38044705 | ||
| An overview of valuable scientific models for diabetes mellitus | Q38099897 | ||
| Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches | Q38548140 | ||
| A month-long effect from a single injection of microencapsulated human growth hormone | Q38563438 | ||
| Biodegradable Polymers for Protein and Peptide Drug Delivery | Q38574913 | ||
| Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. | Q39741884 | ||
| Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases | Q40075194 | ||
| Biological approaches to the controlled delivery of drugs: a critical review. | Q40199551 | ||
| A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices. | Q40362968 | ||
| Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome | Q40370420 | ||
| Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma | Q40443598 | ||
| An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates | Q40663794 | ||
| Vaginal immunization with recombinant gram-positive bacteria. | Q41731866 | ||
| The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes | Q41900249 | ||
| A biochemical and histopathologic study showing protection and treatment of gentamicin-induced nephrotoxicity in rabbits using vitamin C. | Q42016241 | ||
| Development of a long-acting insulin analog using albumin fusion technology | Q42472191 | ||
| Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. | Q42488438 | ||
| Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [¹⁸F]-IL1RA and PET imaging in rats | Q42613642 | ||
| Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins | Q42627131 | ||
| Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. Phospholipase D-derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells | Q42798711 | ||
| The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae | Q43024390 | ||
| A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. | Q43033369 | ||
| Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris | Q43061974 | ||
| Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology | Q43237802 | ||
| IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro | Q43241239 | ||
| Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins | Q43582003 | ||
| Chemical synthesis of cross-linked poly(KGGVG), an elastin-like biopolymer | Q43601243 | ||
| Directed gene copy number amplification in Pichia pastoris by vector integration into the ribosomal DNA locus. | Q43624481 | ||
| Development of expression systems for the production of recombinant human serum albumin using the MOX promoter in Hansenula polymorpha DL-1. | Q43707345 | ||
| Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit | Q44008085 | ||
| Recombinant human elastin polypeptides self-assemble into biomaterials with elastin-like properties | Q44675845 | ||
| Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats. | Q44843172 | ||
| A potential approach for decreasing the burst effect of protein from PLGA microspheres | Q45184985 | ||
| Specificity in the coacervation of tropoelastin: solvent exposed lysines | Q45274761 | ||
| Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist. | Q46231514 | ||
| Injectable, thermo-reversible and complex coacervate combination gels for protein drug delivery | Q46699827 | ||
| Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene | Q47907622 | ||
| The effect of gene copy number and co-expression of chaperone on production of albumin fusion proteins in Pichia pastoris | Q48047224 | ||
| Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. | Q48449950 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| P433 | issue | 11 | |
| P921 | main subject | anakinra | Q415411 |
| P304 | page(s) | 2951-2966 | |
| P577 | publication date | 2013-06-22 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | IL-1Ra and its delivery strategies: inserting the association in perspective | |
| P478 | volume | 30 |
| Q39082143 | Analgesic, anti-inflammatory and anti-pyretic activities of Caesalpinia decapetala. |
| Q30416813 | Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diff |
| Q87176880 | Development and comparison of two competitive ELISAs for estimation of cotinine in human exposed to environmental tobacco smoke |
| Q26852990 | Diabetes mellitus related bone metabolism and periodontal disease |
| Q63248499 | IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection |
| Q37470376 | Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? |
| Q57369611 | Natural and Synthetic Polymers as Drug Carriers for Delivery of Therapeutic Proteins |
| Q57345827 | Protein Therapeutic: Production, Application, and Future Scenario |
| Q38824381 | Synthesis of self-assembled IL-1Ra-presenting nanoparticles for the treatment of osteoarthritis |
Search more.